A Study on Immunotherapy Combined With Radiotherapy for Esophagogastric Junction/Gastric Adenocarcinoma

NCT07053332 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Esophagogastric Junction/Gastric Adenocarcinoma

Interventions

DRUG: PD-1/CTLA-4 combination antibody with low-dose radiotherapy

Sponsor

Jiangsu Cancer Institute & Hospital